Lantheus (NASDAQ:LNTH) Sets New 1-Year High – Should You Buy?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price reached a new 52-week high on Tuesday . The company traded as high as $111.52 and last traded at $111.2550, with a volume of 83991 shares. The stock had previously closed at $109.58.

Analyst Ratings Changes

A number of research analysts recently commented on LNTH shares. Wall Street Zen downgraded shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. William Blair restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Truist Financial reaffirmed a “buy” rating and issued a $115.00 price objective (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $110.00 target price on shares of Lantheus in a report on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Price Performance

The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $7.20 billion, a PE ratio of 26.68 and a beta of -0.03. The stock’s 50-day moving average is $96.39 and its two-hundred day moving average is $80.34.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. During the same quarter in the previous year, the business earned $1.53 earnings per share. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts predict that Lantheus Holdings, Inc. will post 4.49 EPS for the current year.

Institutional Trading of Lantheus

A number of hedge funds and other institutional investors have recently bought and sold shares of LNTH. Western Wealth Management LLC purchased a new stake in shares of Lantheus during the first quarter valued at $25,000. Osterweis Capital Management Inc. purchased a new position in Lantheus in the 2nd quarter worth about $36,000. Smartleaf Asset Management LLC lifted its holdings in Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares in the last quarter. Bessemer Group Inc. lifted its holdings in Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 354 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.